{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:09:37Z","timestamp":1790640577678,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Japan Society for the Promotion of Science (JSPS) through KAKENHI Grant","award":["20H03664, 19K10045"],"award-info":[{"award-number":["20H03664, 19K10045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06689-0","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:50:37Z","timestamp":1761702637000},"page":"6075-6079","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1946-8609","authenticated-orcid":false,"given":"Daisuke","family":"Ogiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-6230","authenticated-orcid":false,"given":"Rikio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-873X","authenticated-orcid":false,"given":"Yosuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miina","family":"Nasukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shino","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-8968","authenticated-orcid":false,"given":"Hidetsugu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6455-3831","authenticated-orcid":false,"given":"Masako","family":"Toyosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"6689_CR1","doi-asserted-by":"crossref","unstructured":"Lin CH, Tariq MJ, Ullah F et al (2024) Current novel targeted therapeutic strategies in multiple myeloma. Int J Mol Sci 25:6192","DOI":"10.3390\/ijms25116192"},{"key":"6689_CR2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","volume":"18","author":"SH Panowski","year":"2019","unstructured":"Panowski SH, Kuo TC, Zhang Y (2019) Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol Cancer Ther 18:2008\u20132020","journal-title":"Mol Cancer Ther"},{"key":"6689_CR3","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29:2259\u20132267","journal-title":"Nat Med"},{"key":"6689_CR4","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R et al (2024) Long-term survival and safety of Elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere 8:e136","journal-title":"Hemasphere"},{"key":"6689_CR5","doi-asserted-by":"publisher","first-page":"54s","DOI":"10.1177\/0091270011413894","volume":"52","author":"B Meibohm","year":"2012","unstructured":"Meibohm B, Zhou H (2012) Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol 52:54s\u201362s","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"6689_CR6","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1016\/j.xphs.2024.07.009","volume":"113","author":"MA Bryniarski","year":"2024","unstructured":"Bryniarski MA, Tuhin MTH, Shomin CD et al (2024) Utility of cellular measurements of non-specific endocytosis to assess the target-independent clearance of monoclonal antibodies. J Pharm Sci 113(10):3100\u20133111","journal-title":"J Pharm Sci"},{"key":"6689_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22:85\u201396","journal-title":"Nat Rev Immunol"},{"key":"6689_CR8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.46989\/001c.116800","volume":"6","author":"Z Van de Wyngaert","year":"2024","unstructured":"Van de Wyngaert Z, Romera-Martinez I, Chedeville C (2024) Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis. Clin Hematol Int 6:46\u201350","journal-title":"Clin Hematol Int"},{"key":"6689_CR9","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3324\/haematol.2024.286233","volume":"109","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Beltran S, Goldfinger M et al (2024) Phenomenon of tumor flare with Talquetamab in a patient with extramedullary myeloma. Haematologica 109:2368\u20132371","journal-title":"Haematologica"},{"key":"6689_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27063","volume":"98","author":"L Joiner","year":"2023","unstructured":"Joiner L, Bal S, Godby KN, Costa LJ (2023) Teclistamab in patients with multiple myeloma and impaired renal function. Am J Hematol 98:E322\u2013e324","journal-title":"Am J Hematol"},{"key":"6689_CR11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1177\/10781552241242022","volume":"30","author":"CJ Khouderchah","year":"2024","unstructured":"Khouderchah CJ, Ochs M, Pianko M et al (2024) Administration of Teclistamab in four patients with multiple myeloma requiring hemodialysis. J Oncol Pharm Pract 30:1089\u20131095","journal-title":"J Oncol Pharm Pract"},{"key":"6689_CR12","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/bjh.19772","volume":"205","author":"P Lebreton","year":"2024","unstructured":"Lebreton P, Lachenal F, Bouillie S (2024) Teclistamab for relapsed refractory multiple myeloma patients on dialysis. Br J Haematol 205:2077\u20132079","journal-title":"Br J Haematol"},{"key":"6689_CR13","unstructured":"Dima D, Afrough A, Goel U et al (2025) Teclistamab for patients with heavily pretreated Relapsed\/Refractory multiple myeloma and renal impairment. Blood Adv"},{"key":"6689_CR14","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood.2019003807","volume":"135","author":"V Royal","year":"2020","unstructured":"Royal V, Leung N, Troyanov S et al (2020) Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood 135:1833\u20131846","journal-title":"Blood"},{"key":"6689_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23416","volume":"34","author":"X Chen","year":"2020","unstructured":"Chen X, Luo X, Zu Y et al (2020) Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. J Clin Lab Anal 34:e23416","journal-title":"J Clin Lab Anal"},{"key":"6689_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387:495\u2013505","journal-title":"N Engl J Med"},{"key":"6689_CR17","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387:2232\u20132244","journal-title":"N Engl J Med"},{"key":"6689_CR18","doi-asserted-by":"crossref","unstructured":"Betjes MG (2020) Uremia-associated ageing of the thymus and adaptive immune responses. Toxins (Basel) 12:224","DOI":"10.3390\/toxins12040224"},{"key":"6689_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.humimm.2021.11.003","volume":"83","author":"KA Lisowska","year":"2022","unstructured":"Lisowska KA, Storoniak H, D\u0119bska-\u015alizie\u0144 A (2022) T cell subpopulations and cytokine levels in hemodialysis patients. Hum Immunol 83:134\u2013143","journal-title":"Hum Immunol"},{"key":"6689_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00011-024-01897-2","volume":"73","author":"W Wu","year":"2024","unstructured":"Wu W, Song A, Xie K et al (2024) Characteristics of T cell premature senescence in maintenance hemodialysis patients. Inflamm Res 73:1299\u20131309","journal-title":"Inflamm Res"},{"key":"6689_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","volume":"109","author":"S Sidana","year":"2023","unstructured":"Sidana S, Peres LC, Hashmi H (2023) Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment. Haematologica 109:777\u2013786","journal-title":"Haematologica"},{"key":"6689_CR22","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.ekir.2020.08.031","volume":"5","author":"B Canaud","year":"2020","unstructured":"Canaud B, Kooman JP, Selby NM et al (2020) Dialysis-induced cardiovascular and multiorgan morbidity. Kidney Int Rep 5:1856\u20131869","journal-title":"Kidney Int Rep"},{"key":"6689_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H (2023) Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 13:116","journal-title":"Blood Cancer J"},{"key":"6689_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01282-0","volume":"15","author":"M Mohan","year":"2025","unstructured":"Mohan M, Szabo A, Cheruvalath H et al (2025) Effect of intravenous Immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J 15:74","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06689-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06689-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06689-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:29Z","timestamp":1764729089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06689-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6689"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06689-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We are complying with the specific requirements of our institution. We have obtained the consent for publication in print and electronically from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"DO received a grant from Johnson & Johnson Inc; DO, RS, MT, and SM received lecture fees from Johnson & Johnson Inc.; MO received lecture fees from Johnson & Johnson Inc., Pfizer and Miyarisan Pharmaceutical Co. YO was granted clinical trial funds as the principal investigator. The remaining authors have no financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}